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432Allogeneic Stem Cell Transplantation Compared with
Chemotherapy for Poor-Risk Hodgkin Lymphoma
Luca Castagna,1 Barbara Sarina,1 Elisabetta Todisco,1 Massimo Magagnoli,1
Monica Balzarotti,1 Stefania Bramanti,1 Rita Mazza,1 Antonella Anastasia,1
Andrea Bacigalupo,2 Franco Aversa,3 Davide Soligo,4 Laura Giordano,5 Armando Santoro1The aim of this study was to assess the role of allogeneic hematopoietic stem cell transplantation (HSCT) in
patients with poor-risk Hodgkin’s disease (HD) compared to chemotherapy. A donor was identified in 26
patients (14 HLA identical siblings and 10 alternative donors), and 24 received a transplant (Allo group).
Twenty patients without a donor received different chemotherapy regimens and radiotherapy (CHEMO
group). After a median follow-up of 28 months (range: 1-110), the 2-year overall survival (OS) was 71% in
the ALLO group compared to 50% in the CHEMO group (P 5 .031). In the Allo group, the 2-year progres-
sion-free survival (PFS) was 47%. The 1-year nonrelapse mortality (NRM) in the ALLO group was 8% versus
0% in the CHEMO group. This study, suggests that allogeneic transplantation may prolong the survival in
patients with a poor-risk HD.
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tationINTRODUCTION
High-dose chemotherapy (HDC) with peripheral
blood stem cell transplantation (PBSC-T) is the stan-
dard therapy for patients with resistant/relapsed
Hodgkin lymphoma (HL) [1,2]. However, the 3- to
5-year progression-free survival (PFS) ranges from
30% to 60%, and the overall survival (OS) from 40%
to 50% [2,3]. The prognosis of patients not cured by
HDC is very poor, with median survival of\1 year
[4,5,6]. The optimal management of this group of pa-
tients remains uncertain, ranging from involved field
radiotherapy in localized disease to single agents1Hematology Oncology Department, Istituto Clinico
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6/j.bbmt.2008.12.506used sequentially or multidrug chemotherapy and
even a second high-dose procedure, supported by
autologous or allogeneic hematopoietic cells [7-9].
Agents such as vinblastine, gemcitabine, and vinorel-
bine, are active in relapsed or refractory HL, but these
therapies are unlikely to be curative [10-12]. Second
HDC with autologous support is rarely considered in
these patients, and should be reserved to patients
with remission; better results are obtained when the re-
mission lasts longer than 12 months after the HDC
[13]. Myeloablative allogeneic hematopoietic stem
cell transplantation (HSCT) seems to offer long-
term survival to approximately 15% of patients, but
it is associated with a high treatment-related mortality
(TRM) rate ranging from 30% to 65% [14,15]. Alloge-
neic stem cell transplantation with a reduced-intensity
conditioning regimen (ALLO-RIC) is less toxic than
conventional allogeneic transplantation, and is consid-
ered the most challenging approach in this patient
subset. The European Blood and Marrow Transplant
(EBMT) group retrospectively reported on 52 poor-
prognosis HL patients showing a 2-year OS and PFS
of 56% and 42%, respectively, and an acceptably low
nonrelapse mortality (NMR) [16]. Other papers re-
ported on the feasibility of allogeneic SCT with RIC
[17,18]. However, in each of these studies only patients
receiving the transplantation were analyzed, and infor-
mation on the general population of relapsed or pro-
gressed HL patients was lacking.
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progressing after HDC in our institute for which a sys-
tematic search for an allogeneic donor was started at
that time, and we compared them with those patients
who did not undergo transplantation.PATIENTS AND METHODS
Between January 1999 and May 2006, 49 consecu-
tive patients with poor-prognosis HL were analyzed.
Three patients considered too ill to receive any kind
of treatment were excluded and 46 were reviewed for
this analysis. Inclusion criteria were as follows:
1. patients refractory to second-line salvage IGEV
regimen [19]. For this cohort of patients, an auto-
allo sequence was planned.
2. patients relapsing or progressing after HDC with
autologous stem cell support program.
According to the policy at our institute during dif-
ferent periods, patients received a single HDC proce-
dure or tandem HDC [20].
For all these patients, the first step was to find an
HLA-identical family donor. In the absence of an
HLA-identical sibling, the second step was to search
for a match unrelated donor (MUD). If MUD was
not found either, the third step was to search for a non-
identical family donor. Some of these patients have
been previously described [21].
Conditioning regimens and graft-versus-host dis-
ease (GVHD) prophylaxis were heterogeneous. Briefly,
HLA-identical transplants were conditioned with 2
combinations of fludarabine and cyclophosphamide
(Flu/Cy): a 5-day scheme (Flu/Cy-1, Flu 25 mg/m2/
day  5 days and Cy 60 mg/kg/day  2 days) and a 3-
day scheme (Flu/Cy-2, Flu 30 mg/m2/day  3 days
and Cy 300 mg/m2/day  3 days) when the patient
had received an HDC course\2 months previously.
In the cohort of patients included in the auto-allo se-
quence, the ‘‘auto phase’’ consisted of melphalan 200
mg/m2 followed by autologous stem cell support, and
the ‘‘allo phase’’ consisted of the Flu/Cy-2 conditioning
regimen. GVHD prophylaxis consisted of cyclosporine
(CsA 3 mg/kg/day), starting from day 21 associated or
not with micromethotrexate (uMTX10 mg/m2 on day
11 and 8 mg/m2 on days13,16,111).
MUD transplants were conditioned with melpha-
lan (Mel) 30 mg/m2 on day –8, campath-1H 20 mg/
day  4 days (from day 28 to day 25), Flu 30 mg/
m2/day  3 days (from day 24 to day 22) and total-
body irradiation (TBI) 200 cGy single dose on day
21. GVHD prophylaxis consisted of CsA 3 mg/kg/
day plusmycophenolatemofetil (MMF30mg/kg/day).
Haploidentical transplants (3-loci mismatched do-
nor) were conditioned with: thiotepa 10 mg/kg (day
–8), Flu 40 mg/m2/days  4 days (from day –7 to
–4), and ATG Fresenius 5 mg/kg/day (from –7 to –3)and PAM 140 mg/m2 (day –3) [22]. For these
patients, GVHD prophylaxis consisted of ex vivo T
cell depletion (CD34-positive selection with the
Miltenyi system).
Donors were mobilized with subcutaneous leno-
gastrim 10 to 16 mg/kg/day divided every 12 hours
from day –4 to leukapheresis. The peripheral stem
cells were harvested using a Cobe Spectra (Denver,
CO) 3000 device on day 0. The target stem cell dose
was fixed at least to 2  106/kg of recipient, for
HLA-identical sibling and unrelated donors.
The Seattle score [23] were used to evaluate acute
GVHD (aGVHD): patients with Glucksberg grade
II–IV were treated with methylprednisolone 2 mg//
kg/day. The response was evaluated after 5 days and,
in the case of a complete remission, the steroid dose
was tapered by 0.3 mg/kg per week. Chronic GVHD
(cGVHD) was classified as extensive or localized ac-
cording to the revised Seattle classification [24]. Pa-
tients with extensive cGVHD received the Seattle
alternate scheme [25] or CsA 12 mg/kg orally daily
andMMF 30mg/kg orally in 3 divided daily doses. Pa-
tients with localized, but symptomatic cGVHD were
also treated with systemic therapy.
Patients with no donor were managed with radio-
therapy and/or conventional chemotherapy according
to their previous treatment and disease extent.
The response was evaluated using the Interna-
tional Working Group criteria [26]. Complete remis-
sion (CR) was defined as a total disappearance of
previous sites of disease for at least 4 weeks; partial re-
mission (PR) as a reduction of at least 50% in the prod-
uct of major diameter, without the appearance of new
lesions for at least 4 weeks; stable disease (SD) as no
change in the lesions, and progressive disease (PD) as
an increase of at least 25% of previous lesions. Patients
with CR and PR before allogeneic transplantation
were considered to have chemosensitive disease,
whereas patients with SD or PD were considered to
have chemoresistant disease.
Statistical Analysis
OS was defined as the time from date of failure of
first HDC to death from any cause or to date of last
follow-up. Survival curves were generated using the
Kaplan-Meier method, and differences between
groups in the univariate analysis were assessed using
the log-rank test. For the ALLO group, PFS was cal-
culated from the date of failure of first HDC to pro-
gression or death for HL, or to last visit date in the
case of no events. A value of P\ .05 was considered
to be the limit of statistical significance.
RESULTS
Patient characteristics at the time of inclusion are
shown in Table 1, with no statistical difference
Table 1. Patient Characteristics at Inclusion
ALLO Group N (%) CHEMO Group N (%)
No. of patients 26 20
Sex
Male 13 (50) 15 (75)
Female 13 (50) 5 (25)
Median age (range) 20 (18-44) 29 (19-43)
Previous radiotherapy
Yes 17 (65) 12 (60)
No 9 (35) 8 (40)
Previous HDC
Single course 15 (58) 14 (70)
Double HDC 11 (42) 6 (30)
Stage at inclusion
I-II 8 (31) 6 (30)
III-IV 18 (69) 14 (70)
Bulky disease
Yes 2 (8) 4 (20)
No 24 (92) 16 (80)
B-symptoms
Yes 2 (8) 2 (10)
No 24 (92) 18 (90)
Disease status
before Allo*
CR 5 (21)
PR 7 (29)
PD 5 (21)
SD 7 (29)
Donor type
HLA-identical sibling 14 (54)
HLA-mismatched sibling 2 (8)
Haploidentical relative 4 (15)
MUD 6 (23)
Median follow-up (range) 30 months (5-110) 23 months (1-87)
MUD indicates matched unrelated donor; CR, complete remission; PR,
partial remission; allo, allogeneic transplantation; PD, progressive dis-
ease; SD, stable disease; HDC, high-dose chemotherapy.
*Two patients with donor did not receive allogeneic transplantation.
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treatments, based on donor availability, is illustrated
in Figure 1.
Twenty-six of 46 patients (56%) had a donor. Of
these patients, 31% (8 of 26) were included in an
‘‘auto-allo’’ program, and 69% (18 of 26) relapsed or
progressed after HDC. In 20 patients (44%) it was
not possible to find a donor, and they received several
chemotherapy regimens and/or radiotherapy. For pa-
tients treated after HDC, the median time to treat-
ment failure (TTF) after HDC was 5 months (range:
1-30). Twenty-four patients out of 26 (92%) with a do-
nor received allogeneic transplantation. All patients
received debulking treatment before allogeneic trans-
plantation. Two patients with a donor did not receive
allogeneic transplantation because of disease refrac-
tory to several chemotherapies and poor performance
status. Eight patients (30%) were treated within an
auto-allo program; 3 patients (12%) with progressive
disease after a first HDC course received a second
noncrossreactive HDC; 13 patients (58%) received
different salvage chemotherapies. Disease status at
the time of allogeneic transplantation (n 5 24) was as
follows: 29% (n 5 7) were in PR, 21% (n 5 5) inCR, 21% (n 5 5) had PD, and 29% (n 5 7) had SD.
Overall, 79% of patients with active disease were trans-
planted.
Twenty patients with no donor available were
treated with several regimens (Table 2). Two patients
(10%) received a second noncrossreactive HDC, 25%
(n5 5) received 1 line of chemotherapy, 60% (n5 12)
received.2 lines, and 1 patient received involved field
radiotherapy. After these therapies, 25% (n 5 5) were
in CR and 75% (n 5 15) progressed.Survival
After a median follow-up of 28 months (range: 1-
110), the median OS for all patients was 27 months
(Figure 2). In the intention-to-treat analysis, the me-
dian OS was 31 months for the ALLO group, and
this did not reach statistical significance compared to
patients not receiving allogeneic stem cell transplanta-
tion, where OS reached 22 months (P5 .056). The 2-
year OS was 65% and 50%, in the ALLO group and
CHEMO group, respectively. When the OS was cal-
culated including patients receiving ALLO (n 5 44),
there was a statistically significant difference (31
months versus 22 months, P 5.031, HR in ALLO
group versus CHEMO group 5 0.45 (confidence in-
terval [CI] 95%: 0.21; 0.95) (Figure 3). The 2-year
OS was 71% and 50%, respectively. No difference
was found on analyzing the OS in the ALLO group be-
tween patients with chemosensitive and those with
chemoresistant disease (P 5 .610) or according to the
duration of response after the HDC (.12 months
versus\12 months (P 5 .174). For the ALLO group,
the median PFS was 14 months, the 2-year PFS was
41% (Figure 4).
Survival was analyzed separately for patients in-
cluded in the ‘‘auto-allo’’ program, because in this
cohort, allogeneic transplantation was applied early
based on no response to second-line chemotherapy.
The 2-year OS and PFS were 75% and 50%, respec-
tively, and thus not significantly different from the
whole cohort.
All but 1 patient who relapsed after allogeneic
transplantation (n 5 12) were retreated. The only pa-
tient not treated was considered too ill. Five patients
received donor lymphocyte infusions (DLIs); the me-
dian number was 2 reinfusions (range: 1-8) and theme-
dian CD31 cell dose was 108/kg (range: 107-108/kg).
All but 1 patient progressed, and 1 obtained a PR. After
DLIs, 2 patients developed extensive cGVHD. Multi-
agent regimens were administered to 6 patients and ra-
diotherapy to 9 patients. Overall, 31% (4 of 13) were
alive, but only 1 without disease. The median OS for
these patients was 15 months.
At last follow-up, 12 patients (50%) who received
allogeneic stem cell transplantation were alive: 9
(37%) without and 3 with disease (Table 3). On the
Patients
n=46
Donor not found
n=20
Donor identified
n=26 
Mismatched sibling
n=14
Mismatched related
n=2
Not done for
poor PS
n=2
Haploidentical
n=4
MUD
n=4
Figure 1. Allocation to different treatments based on donor availability.
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were alive without disease. HL was the only cause of
death in the CHEMO group.Table 3. Conventional Therapies in Patienst without Donor
Pts Chemotherapies
ZM RT, Chlorambucil, VBM, VNR + GEM
BC RT, Vinblastine
PB ESHAP
ZP DHAP, Chlorambucil
SP Chlorambucil, ChlVPP, DHAP
GT ChlVPP
MP ChlVPP
BF ChlVPP, GEM
BL DHAP, ChlVPP, VBM
ZC MOPP, VNR, IGEV, ChlorambucilALLO Toxicity
The median number of CD341 cells infused was
6.6  106/kg (range: 2.1-16). All patients engrafted
and the median time to reach an absolute neutrophil
count (ANC) .0.5  109/dL and 1.0 was 12 days
(range: 0-42) and 14 days (range: 0-56), respectively.
The median time to platelet recovery .20  109/dL
and 50  109/dL was 1 day (range: 0-33) and 11 days
(range: 0-42), respectively. All evaluable patients (22
of 24) showed full donor chimerism between 100 and
120 days after transplantation.
Nine patients developed pneumonia, 6 of them
\100 days after transplantation. The pneumonia was
associated with a viral infection (cytomegalovirus
[CMV] and HHV-6 plus adenovirus) in 2 patients
and Pneumocystis jirovecii in 1 patient. Others infective
complications were: sepsis (3), clostridium infection
(1), dermatomeric herpes zoster (1), urinary tract in-
fection with stenotrophomonas (1). CMV infection
was detected in 3 patients and 1 patient developed
Epstein-Barr virus (EBV)-related lymphoproliferative
lung disease.
aGVHD occurred in 36% of evaluable patients (8
of 22). In all but 1 patient, aGVHDwas grade I-II, and
6 of them were treated with steroids. Two patientsTable 2. Status at Last Follow-up
ALLO Group N (%) CHEMO Group N (%)
No. of Patients 24 20
Status
Alive 12 (50) 4 (20)
Dead 12 (50) 16 (80)
HL 10 (42) 15 (94)
TRM 2 (8) 0 (0)
Unknown 0 (0) 1 (6)
Disease status
ED 3 (12) 0 (0)
NED 9 (38) 4 (20)
HL indicates Hodgkin’s lymphoma; TRM, treatment-related mortality;
ED, evidence disease; NED, non evidence disease.developed grade IV aGVHD after DLI was performed
for immunologic reconstitution and progressive dis-
ease. GVHD was fatal in 1 patient. Twenty-one pa-
tients were evaluable for cGVHD, and 48% (10 of
21) of them developed this complication; it was limited
in 3 and extensive in 7.
The nonrelapse-related mortality (NRM) was 4%
at 100 days and 8% at 1 year. The causes of death
were pneumonia and post-DLI aGVHD.DISCUSSION
HL progression following HDC and autologous
PBSC-T is not uncommon, and the prognosis of
patients is poor. In these patients, there is no defined
strategy, and often in the past, the general approach
consisted only in palliative care, with a reported sur-
vival of around 10 months [9,27]. Only a few data areAP DHAP
LD CAELYX, GEM, Vinblastine
CS RT
LE HDC, GEM
LC ChlVPP
AR ChlVPP, CTX+VP16, GEM
SS IGEV, DHAP
PG DHAP, ABVD, ChlVPP
SP GEMCITABINE + VNR, Rituximab
SG ESHAP, HDC
ChlVPP indicates Chlorambucil, Vinblastine, Procarbazine Prednisone;
VBM, Vinblastine, Bleomicina, Methotrexate; DHAP, cisplatin, cytosine
arabinoside, dexamethasone; IGEV, ifosfamide, gemcitabine, vinorelbine,
prednisolone; VNR, vinorelbine; GEM, gemcitabine; HDC, high-dose
chemotherapy; ESHAP, Etoposide, cytosine arabinoside, cisplatin, pred-
nisone; MOPP, mechloretamine, vincristine, procarbazine, prednisone;
ABVD, doxorubicin, bleomycin, vinblastine, dacarbazine; pts, patients.
Figure 4. PFS for patients receiving Allo (n 5 24).Figure 2. OS for all patients (n 5 46).
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and no firm conclusions are possible [13,28].
Myeloablative allogeneic transplantation in HL
has historically been restricted by the high NRM,
even if a graft-versus-HL reaction has been suggested
[14,15]. Because of this, myeloablative allogeneic
transplantation did not show any survival advantage
over other therapies for these patients. Recently, the
EBMT group reported that allogeneic transplantation
with RIC is significantly less toxic than myeloablative
transplantation (1-year NRM 23% versus 46%), with
better OS (28% versus 22%). However, the relapse
rate, particularly after TBI-based RIC, was higher in
the RIC group [29].
More recently, the use of RIC before allogeneic
stem cell transplantation to reduce theNRMand allow
detection of a graft-versus-lymphoma effect has re-
ceived renewed interest in this setting [17,30-32]. InFigure 3. OS for patients receiving ALLO (dotted line) versus other
treatments (solid line) (n 5 44).all these studies, RIC was feasible in patients relapsing
after HDC, with NRM ranging from 16% to 35% and
a 2-to 3-year OS and PFS ranging from 32% to 64%
and 11% to 55%, respectively. The largest study pub-
lished from the EBMT data on 374 patients showed
that the 2-year OS and PFS were 40% and 29%, re-
spectively.
However, the results reported in the literature are
evaluated only for patients receiving allogeneic trans-
plantation, whereas no data are available for patients
relapsing after HDC not treated with allogeneic trans-
plantation. Recently, in a case-controlled study of 38
patients receiving an alemtuzumab-based ALLO-
RIC were compared with 34 historic patients who re-
lapsed after HDC and were treated conventionally.
The 5-year OS was statistically higher for ALLO-
RIC patients than for the control group (48% versus
15%), and the 5-year PFS in the ALLO group was
42%. This study suggests that allogeneic transplanta-
tion should be strongly considered in poor-prognosis
HL patients [33].
In the present study, we analyzed the data on 46
consecutive poor-risk HL patients followed in our in-
stitution and candidates for allogeneic transplantation.
Inclusion criteria were failure of HDC and not CR af-
ter the first salvage chemotherapy. This second group
of patients was considered to have a poor prognosis
[34]. At time of inclusion, a search for an HLA-identi-
cal sibling was started for all patients, and if none was
available, a donor search was launched in a matched
unrelated registry. Finally, when an HLA identical do-
nor was not found, the availability of a nonidentical
family donor was explored. Consequently, we were
able to compare 2 groups of patients on the basis of do-
nor availability. After a median follow-up of 28 months,
the OS was significantly better in the ALLO group
of patients who received allogeneic transplantation
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ysis of OS was calculated in an intention-to-treat anal-
ysis, the significativity was slightly lower. At last
follow-up, more patients in the ALLO group were
alive compared to conventionally treated patients
(50% versus 20%). The 1-year NRM in the ALLO
group was low at only 8%. These results are in line
with those previously reported, and confirm that allo-
geneic transplantation can cure a proportion of pa-
tients failing HDC. However, they clearly confirm
that to reserve this treatment to the late phase of the
disease when HDC has failed could jeopardize its full
therapeutic potential. One of the most important
prognostic factors predictive of survival after ALLO-
RIC is the disease status before transplantation
[16,29,35]. In fact, the widespread use of [18-F]-fluoro-
deoxyglucose-positron emission tomography (FDG-
PET) allows this response to be defined more
accurately, and, consequently, for patients with differ-
ent prognosis to be distinguished [36,37]. In the pres-
ent cohort, 8 patients were treated because they were
not in complete remission after second-line chemo-
therapy, and the survival was not different compared
to the whole population. However, more patients
should be treated to allow definitive conclusions.
Another point of discussion is how much the con-
ditioning regimen should be reduced in patients with
HL. In this study, conditioning regimens were quite
heterogeneous, and no firm conclusions can be drawn.
However, more ‘‘intensive’’ conditioning regimens
(mainly Mel based) seemed to reduce the relapse rate
compared to less intensive low-dose TBI-based RIC
[29,38]. Furthermore, it has been suggested that
when alemtuzumab was added to RIC, the 4-year OS
and PFS were significantly better (62% versus 39%
and 39% versus 25%, respectively) compared to anti-
body free RIC [35]. These results were associated
with a lower NRM after alemtuzumab-based RIC
(7% versus 29%, respectively) and with a more durable
response after DLI.
The results of this study should be interpreted
with caution because of several limitations such as
the small cohort of patients analyzed, the heteroge-
neity of the conditioning regimens and immunos-
uppressive schemes, the short follow-up, and the
nonrandomized nature. On the other hand, all patients
with inclusion criteria were ‘‘enrolled’’ in this study,
thus providing a denominator.
In conclusion, the majority of poor-prognosis HL
patients treated with a ‘‘conventional’’ approach have
a poor clinical course after failure of HDC. Allogeneic
transplantation seems to prolong the survival of HL
patients who have relapsed and are refractory after
HDC. ALLO-RIC should probably be performed at
an early phase of the disease, that is, in patients who
are PET-positive after salvage chemotherapy, possibly
preceded by a debulking phase with HDC.ACKNOWLEDGMENTS
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